摘要
目的:研究新安软胶囊对大鼠脂肪肝模型动物的影响。方法:建立大鼠脂肪肝动物模型后,以血清中生化指标(ALT、AST、LDL、HDL-C)测定、血清和组织中CHO、TG、MDA、SOD含量测定等为检测指标,比较新安软胶囊的量效与时效关系。结果:①每个新安软胶囊组与模型组及对照组比较均能明显降低ALT、AST、LDL、CHO、TG、MDA、SOD(P<0.05),以及明显升高HDL-C(P<0.05),其剂量效果是新安软胶囊62.5 mg/kg组<125mg/kg组<250 mg/kg组,其时间效果是用药后第2周<第4周<第6周;②新安软胶囊中、大剂量组与模型组比较有明显统计学差异(P<0.05)。结论:新安软胶囊对大鼠脂肪肝模型具有明显的治疗作用。
Objective： To investigate the effect on adiposis hepatica Rats ＇model. Methods： To investigate the dose-and time-ef- fect by using serum biochemical parameters （ALT, AST, LDL, HDL-C） measured in serum and tissues CHO, TG, MDA, SOD assay as index. Results： （i） Xin＇an soft capsules each with the model group and control group could reduce the ALT, AST, LDL, CHO, TG, MDA, SOD （P 〈0.05）, and significantly increased HDL-C （P 〈0.05）, the dose effect of Xin＇an soft capsules was 62.5mg/kg group 〈125mg/kg group 〈 250mg/kg group, the time effect was two weeks 〈four weeks 〈six weeksafter treatment; （2） Xin＇an soft capsules＇ hitch-dose group with the model group was statistically significant differences （P〈0.05）. Conclusion： Xin＇an soft capsule on adiposis hepatica Rats ＇model has obviously therapeutic effect.
出处
《现代生物医学进展》
CAS
2012年第30期5805-5810,5830,共7页
Progress in Modern Biomedicine
基金
陕西省"13115"科技创新项目(2008ZDKG-61)
